VivoSeq
Infectious Disease

Plasmodium Falciparum Infection

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Plasmodium Falciparum Infection is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Withdrawn1 · 50%

Clinical Trials

Trial Activity

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT05974267·192 enrolled
Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection
Withdrawn·Centers for Disease Control and Prevention·Phase 2/3·NCT01082718

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)